Alzheimer's disease (AD) can be challenging for everyone, especially patients who are looking for answers and a path to the right treatment. The Elecsys® Phospho-Tau (181P) CSF (pTau181) / β-Amyloid (1-42) CSF II (Abeta 42) ratio has 90% concordance with β‑Amyloid PET scan results.¹ The Elecsys® AD CSF (cerebrospinal fluid) assays combine both Abeta42 and pTau181 to give accurate and reliable results that can identify AD pathological changes occurring in early stages of the disease.¹ Early diagnosis of AD may enable timely interventions that alleviate symptoms or slow disease progression, preserving life's moments longer.